Effects of simvastatin on bone mineral density and remodeling parameters in postmenopausal osteopenic subjects: 1-year follow-up study

Clinical Rheumatology

Volumn 24, Issue 5, 2005, Pages 447-452

  Tikiz, Canan ^a,b   Tikiz, Hakan ^a   Taneli, Fatma ^a   Gümüşer, Gül ^a   Tüzün, Çiǧdem ^a  

^a CELAL BAYAR UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Bone mineral density; Bone remodeling; Osteoporosis; Simvastatin; Turnover

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CHOLESTEROL; COLLAGEN TYPE 1; OSTEOCALCIN; PARATHYROID HORMONE; SIMVASTATIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CHEMOLUMINESCENCE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMORBIDITY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; LONG TERM CARE; MUSCLE WEAKNESS; OPEN STUDY; OSTEOPENIA; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; ALKALINE PHOSPHATASE; BONE AND BONES; BONE DENSITY; BONE REMODELING; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; SIMVASTATIN;

EID: 30344469372     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-004-1053-x     Document Type: Article

References (33)

1. Takemoto M, Liao JK (2001) Pleiotropic effects of 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21:1712-1719
2. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949 10.1126/science.286.5446.1946
3. Massy ZA, Keane WF, Kasiske BL (1996) Inhibition of the mevalonate pathway: Benefits beyond cholesterol reduction. Lancet 347:102-103
4. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe N (2001) Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomized controlled trial. Lancet 357:509-512 10.1016/S0140-6736(00)04042-3
5. van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C (2001) Use of statins and risk of fractures. JAMA 285:1850-1855 10.1001/ jama.285.14.1850
6. Lacroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE, Mcneeley G, Passaro MD, Jackson RD (2003) Statin use, clinical fracture, and bone density in postmenopausal women: Results from the Women's Health Initiative Observational Study. Ann Intern Med 139:97-104 1:CAS:528:DC%2BD3sXmtFWrsrk%3D
7. Wang PS, Solomon DH, Mogun H, Avorn J (2000) HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283:3211-3216 10.1001/jama.283.24.3211
8. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R (2000) Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355:2185-2188 10.1016/S0140-6736(00)02400-4
9. Pasco J, Kotowicz M, Henry M, Sanders K, Nicholson G (2002) Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 162:537-540 10.1001/archinte.162.5.537
10. Bauer D, Mundy G, Jamal S, Black DM, Cauley JA, Ensrud KE, van der Klift M, Pols HA (2004) Use of statins and fracture: Results of four prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 164:146-152 10.1001/ archinte.164.2.146
11. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283:3205-3210 10.1001/jama.283.24.3205
12. Edwards CJ, Hart DJ, Spector TD (2000) Oral statins and increased bone mineral density in postmenopausal women. Lancet 355:2218-2219 10.1016/ S0140-6736(00)02408-9
13. Wada Y, Nakamura Y, Koshiyama H (2000) Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med 160:2865 10.1001/archinte.160.18.2865
14. Bjarnason NH, Riis BJ, Christiansen C (2001) The effect of fluvastatin on parameters of bone remodeling. Osteoporos Int 12:380-384
15. Sirola J, Honkanen R, Kroger H, Jurvelin JS, Maenpaa P, Saarikoski S (2002) Relation of statin use and bone loss: A prospective population-based cohort study in early postmenopausal women. Osteoporos Int 13:537-554 10.1007/s001980200070
16. Cauley J, Jackson R, Pettinger M (2000) Statin use and bone mineral density (BMD) in older women: The Women's Health Initiative Observational Study (WHI-OS). J Bone Miner Res 15 [Suppl 1]:1068
17. Rejnmark L, Buus NH, Vestergaard P, Andreasen F, Larsen ML, Mosekilde L (2002) Statins decrease bone turnover in postmenopausal women: A cross-sectional study. Eur J Clin Invest 32:581-589 10.1046/ j.1365-2362.2002.01024.x
18. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA (2000) HMG CoA-reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 85:1137-1142
19. Chan MH, Mak TW, Chiu RW, Chow C, Chan IH, Lam CW (2001) Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolemia. J Clin Endocrinol Metab 86:4556-4559
20. Stein EA, Farnier M, Waldstreicher J, Mercuri M (2001) Effects of statins on biomarkers of bone metabolism: A randomized trial. Nutr Metab Cardiovasc Dis 11:84-87 1:CAS:528:DC%2BD3MXltFWltLg%3D
21. Mostaza JM, De la Piedra C, Curiel MD, Pena R, Lahoz C (2001) Pravastatin therapy increases procollagen I N-terminal propeptide. Clin Chim Acta 308:133-137 10.1016/S0009-8981(01)00476-4
22. Staal A, Frith JC, French MH, Swartz J, Güngör T, Harrity TW, Tamasi J, Rogers MJ, Feyen JH (2003) The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG CoA-reductase activity. J Bone Miner Res 18:88-96 1:CAS:528:DC%2BD3sXltFKksg%3D%3D
23. Bauer DC (2003) HMG CoA reductase inhibitors and the skeleton: A comprehensive review. Osteoporos Int 14:273-282 10.1007/s00198-002-1323-x
24. Nussbaum S, Potts JT 1994 Advances in immunoassays for parathyroid hormone. Clinical applications to skeletal disorders of bone and mineral metabolism. In: Bilezikian JP Levine MA Marcus R (eds) The parathyroids: basics and clinical concepts. Raven, New York, 157-169
25. World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, Geneva
26. Maeda T, Matsunuma A, Kawane T, Horiuchi N (2000) Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 280:874-877
27. Stein GS, Lian JB (1993) Molecular mechanism mediating proliferation/ differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev 14:424-444 10.1210/er.14.4.424
28. Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T, Fujita T (2001) Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med 110:584-587 10.1016/S0002-9343(01)00679-9
29. Khosla S (2003) Parathyroid hormone plus alendronate. A combination that does not add up. N Engl J Med 349:1277-1279
30. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16:1846-1853 1:CAS:528:DC%2BD3MXnsVKqtLw%3D
31. Hock JM, Gera I (1992) Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 7:65-72
32. Cummings S, Black D, Thompson D, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280:2077-2082 10.1001/ jama.280.24.2077
33. McClung M, Geusens P, Miller P, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effects of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340 10.1056/NEJM200102013440503